WFN Press Releases

The Nominating Committee of the World Federation of Neurology now recommends to the membership candidates for WFN President, Vice-President and Elected Trustee.

The World Federation of Neurology is delighted to announce the appointment of Prof. Imen Kacem and Prof. Briseida Feliciano-Astacio as co-opted Trustees. 

We are pleased to announce that Dr Jemima Yeboah from Ghana will begin training in early 2025.

The World Federation of Neurology is pleased to invite bids to host the World Congress of Neurology (WCN) in 2029 from national member society Presidents and Delegates in Europe at a suitable venue.

Learn how to become a global advocacy leader with a new program from the AAN and the World Federation of Neurology (WFN). Applications for the Global Advocacy Leadership Program are open to August 14, 2024.

The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22. The goal is to raise critical awareness to prevent brain disease in all corners of the globe.

Thirteen teams competed in the initial knock-out phase, including several departmental teams from India and teams from Sri Lanka, Japan, Kenya, Mexico, UK, Sudan and Hong Kong.

Africa currently experiences some of the most extreme shortages of neurologists and health care funding and some of the highest rates of disability due to neurological disorders in the world. Dr. Augustina Charway-Felli, president of the African Academy of Neurology, recently proposed a plan for addressing these disparities by emphasizing regional training to increase the number of neurologists throughout Africa and prioritizing education for primary care providers and non-specialists.

There is a growing call to embrace patient engagement in the world of health care, and Kathy Oliver, chair of the International Brain Tumour Alliance (IBTA), is one of many patient advocates at the vanguard of this movement around the world. Patient organizations like IBTA are increasingly at the forefront of patient engagement across various health care domains, including in the design of clinical trials, drug development, health care policy, pricing and reimbursement decisions, and regulatory issues.

One of the central challenges of Amyotrophic Lateral Sclerosis ALS research is finding ways to slow the progression of the relentlessly degenerative brain disease. Recently, based on results of the HEALEY ALS Platform Trial, two experimental medications plan to move to phase 3 clinical trials. This means the drugs will now be tested on a larger sample population to confirm promising early results that showed they can slow the progression of ALS. Phase 3 trials are the last step before drugs are submitted for FDA approval.